CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
Miners
John
J
Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University, Bedford Park, Adelaide, SA, Australia.
D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases; D001786:Blood Glucose / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004341:Drug Evaluation; D005838:Genotype; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics*; D015810:Linkage Disequilibrium; D006899:Mixed Function Oxygenases / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D011159:Population Surveillance; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics*; D014044:Tolbutamide / Q000493:pharmacokinetics*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D003577:Cytochrome P-450 Enzyme System; D014044:Tolbutamide; D006899:Mixed Function Oxygenases; D013250:Steroid Hydroxylases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D039181:Steroid 16-alpha-Hydroxylase